« Back to Record
Citation APA

Harding, J. J., Awada, A., Roth, G., Decaens, T., Merle, P., Kotecki, N., Dreyer, C., Ansaldi, C., Rachid, M., Mezouar, S., Menut, A., Bestion, E. N., Paradis, V., Halfon, P., Abou-Alfa, G. K., & Raymond, É. E. (2022). First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers. Liver Cancer, 11(3), 268-277. doi:10.1159/000522418


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/345909

Harding, J. J., Awada, A., Roth, G., Decaens, T., Merle, P., Kotecki, N., Dreyer, C., Ansaldi, C., Rachid, M., Mezouar, S., Menut, A., Bestion, E. N., Paradis, V., Halfon, P., Abou-Alfa, G. K., & Raymond, É. E. (2022). First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers. Liver Cancer, 11(3), 268-277. doi:10.1159/000522418